HYB timeline
Every HYB batch the index holds, newest manufacture date first, with the supplier's declared purity beside the median of the index's independent observations of the same lot.
| Lot | Compound | Manufactured | Quarter | Tests | Independent median | Spread (pp) | COA purity | Divergence (pp) | |
|---|---|---|---|---|---|---|---|---|---|
| HYB-2608-E7391 | CJC-1295 with DAC | 02 Aug 2026 | 2026-Q3 | 1 | 99.38 | n<2 | 99.63 | +0.25 | |
| HYB-2606-D7858 | MOTS-c | 18 Jun 2026 | 2026-Q3 | 11 | 99.54 | 1.64 | 99.35 | -0.19 | |
| HYB-2604-D6658 | Retatrutide | 15 Apr 2026 | 2026-Q2 | 2 | 98.61 | 0.14 | 98.64 | +0.03 | |
| HYB-2603-U7133 | Epitalon | 16 Mar 2026 | 2026-Q2 | 4 | 99.80 | 0.28 | 99.56 | -0.24 | |
| HYB-2512-P8025 | BPC-157 | 30 Dec 2025 | 2026-Q1 | 3 | 99.51 | 0.55 | 100.00 | +0.49 | |
| HYB-2512-W7237 | Tirzepatide | 12 Dec 2025 | 2026-Q2 | 6 | 98.84 | 0.44 | 98.74 | -0.10 | |
| HYB-2512-B7307 | Triptorelin | 02 Dec 2025 | 2026-Q1 | 12 | 99.46 | 0.71 | 99.42 | -0.04 | |
| HYB-2512-B6579 | SS-31 (Elamipretide) | 01 Dec 2025 | 2026-Q2 | 6 | 99.68 | 0.57 | 99.75 | +0.07 | |
| HYB-2511-P7317 | KPV | 24 Nov 2025 | 2026-Q1 | 2 | 99.64 | 0.09 | 99.87 | +0.23 | |
| HYB-2511-F6451 | Semaglutide | 11 Nov 2025 | 2026-Q2 | 6 | 98.61 | 0.80 | 98.80 | +0.19 | |
| HYB-2511-R7904 | GHRP-6 | 03 Nov 2025 | 2025-Q4 | 2 | 99.87 | 0.13 | 99.90 | +0.03 | SHARED BULK |
| HYB-2510-R7319 | Melanotan II | 31 Oct 2025 | 2026-Q1 | 1 | 99.93 | n<2 | 99.90 | -0.03 | |
| HYB-2510-B7770 | CJC-1295 (no DAC) | 21 Oct 2025 | 2025-Q4 | 1 | 99.83 | n<2 | 99.90 | +0.07 | |
| HYB-2510-H6122 | Semaglutide | 18 Oct 2025 | 2025-Q4 | 7 | 99.53 | 1.03 | 99.90 | +0.37 | |
| HYB-2510-J7470 | Melanotan II | 17 Oct 2025 | 2026-Q1 | 2 | 99.04 | 0.84 | 99.33 | +0.29 | |
| HYB-2510-J6404 | Enclomiphene citrate | 13 Oct 2025 | 2025-Q4 | 2 | 99.32 | 0.58 | 98.87 | -0.45 | |
| HYB-2509-W6465 | Retatrutide | 30 Sep 2025 | 2026-Q1 | 9 | 98.23 | 1.63 | 98.25 | +0.02 | |
| HYB-2509-K6966 | PT-141 (Bremelanotide) | 28 Sep 2025 | 2025-Q4 | 3 | 99.27 | 0.52 | 99.43 | +0.16 | |
| HYB-2509-J7103 | Tirzepatide | 21 Sep 2025 | 2026-Q1 | 5 | 98.00 | 0.71 | 97.68 | -0.32 | |
| HYB-2509-X7841 | MGF | 05 Sep 2025 | 2025-Q4 | 9 | 99.74 | 0.37 | 99.83 | +0.09 | |
| HYB-2507-Y7485 | IGF-1 LR3 | 20 Jul 2025 | 2025-Q3 | 12 | 98.90 | 1.41 | 99.61 | +0.71 | |
| HYB-2507-A6586 | Tirzepatide | 07 Jul 2025 | 2025-Q3 | 5 | 99.93 | 0.26 | 99.90 | -0.03 | |
| HYB-2505-M6859 | MK-677 (Ibutamoren mesylate) | 22 May 2025 | 2025-Q2 | 5 | 99.87 | 0.11 | 99.90 | +0.03 | |
| HYB-2504-N7248 | CJC-1295 (no DAC) | 03 Apr 2025 | 2025-Q3 | 9 | 99.27 | 1.04 | 99.73 | +0.46 | |
| HYB-2502-S7614 | L-Glutathione (reduced) | 28 Feb 2025 | 2025-Q2 | 12 | 99.39 | 0.64 | 99.34 | -0.05 | |
| HYB-2502-R6185 | BPC-157 | 11 Feb 2025 | 2025-Q1 | 2 | 99.85 | 0.16 | 99.90 | +0.05 | |
| HYB-2501-T6290 | Dihexa | 09 Jan 2025 | 2025-Q2 | 6 | 99.64 | 0.54 | 99.62 | -0.02 | |
| HYB-2501-R7240 | GHRP-2 | 08 Jan 2025 | 2025-Q1 | 12 | 99.86 | 0.36 | 99.90 | +0.04 | |
| HYB-2409-X6061 | BPC-157 | 14 Sep 2024 | 2024-Q4 | 11 | 99.30 | 0.65 | 99.00 | -0.30 | |
| HYB-2408-W6301 | Tirzepatide | 15 Aug 2024 | 2025-Q1 | 5 | 99.01 | 1.16 | 101.00 | +1.99 | |
| HYB-2408-N7131 | Enclomiphene citrate | 13 Aug 2024 | 2024-Q4 | 4 | 99.73 | 0.48 | 99.90 | +0.17 | |
| HYB-2408-V7440 | Tirzepatide | 11 Aug 2024 | 2024-Q3 | 3 | 98.68 | 0.77 | 99.52 | +0.84 | |
| HYB-2408-R7015 | Tirzepatide | 06 Aug 2024 | 2025-Q1 | 5 | 98.30 | 0.49 | 98.81 | +0.51 | |
| HYB-2407-J6692 | Exenatide | 29 Jul 2024 | 2024-Q3 | 9 | 98.74 | 1.53 | 99.08 | +0.34 | |
| HYB-2407-V6435 | Semaglutide | 17 Jul 2024 | 2024-Q4 | 11 | 98.93 | 1.14 | 99.54 | +0.61 | |
| HYB-2407-N7367 | Hexarelin | 07 Jul 2024 | 2024-Q3 | 11 | 99.93 | 0.58 | 99.58 | -0.35 | |
| HYB-2407-W6594 | Retatrutide | 05 Jul 2024 | 2024-Q3 | 10 | 98.36 | 0.87 | 98.96 | +0.60 | |
| HYB-2405-C7630 | Selank | 10 May 2024 | 2024-Q2 | 1 | 99.70 | n<2 | 99.20 | -0.50 | |
| HYB-2405-B6705 | CJC-1295 (no DAC) | 07 May 2024 | 2024-Q2 | 6 | 99.17 | 1.48 | 98.61 | -0.56 | |
| HYB-2403-B7301 | ARA-290 | 24 Mar 2024 | 2024-Q3 | 8 | 99.34 | 0.72 | 99.70 | +0.36 |